{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T02:55:15Z","timestamp":1773888915259,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.biopha.2016.11.041","type":"journal-article","created":{"date-parts":[[2016,11,20]],"date-time":"2016-11-20T10:33:12Z","timestamp":1479637992000},"page":"1510-1512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous \u03b2-thalassaemia"],"prefix":"10.1016","volume":"84","author":[{"given":"Sarah","family":"Allegra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"De Francia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filomena","family":"Longo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Massano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Cusato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Arduino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Pirro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Piga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"D'Avolio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.biopha.2016.11.041_bib0005","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s10038-004-0202-z","article-title":"The role of HFE mutations on iron metabolism in beta-thalassemia carriers","volume":"49","author":"Martins","year":"2004","journal-title":"J. Hum. Genet."},{"issue":"2","key":"10.1016\/j.biopha.2016.11.041_bib0010","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1053\/j.gastro.2010.06.013","article-title":"Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment","volume":"139","author":"Pietrangelo","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2016.11.041_bib0015","series-title":"Exjade (deferasirox) Prescribing Information","author":"EEPAR","year":"2007"},{"issue":"12","key":"10.1016\/j.biopha.2016.11.041_bib0020","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2174\/0929867033457610","article-title":"Development of tridentate iron chelators: from desferrithiocin to ICL670","volume":"10","author":"Nick","year":"2003","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.biopha.2016.11.041_bib0025","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/978-1-4615-0593-8_10","article-title":"ICL670A: preclinical profile","volume":"509","author":"Nick","year":"2002","journal-title":"Adv. Exp. Med. Biol."},{"issue":"5","key":"10.1016\/j.biopha.2016.11.041_bib0030","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1124\/dmd.109.030833","article-title":"Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state","volume":"38","author":"Waldmeier","year":"2010","journal-title":"Drug Metab. Dispos."},{"issue":"12","key":"10.1016\/j.biopha.2016.11.041_bib0035","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1124\/dmd.108.022962","article-title":"Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats","volume":"36","author":"Bruin","year":"2008","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.biopha.2016.11.041_bib0040","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1586\/17512433.1.2.231","article-title":"Once-daily oral deferasirox for the treatment of transfusional iron overload","volume":"1","author":"Galanello","year":"2008","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.biopha.2016.11.041_bib0045","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.clinthera.2007.05.007","article-title":"Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia","volume":"29","author":"Cappellini","year":"2007","journal-title":"Clin. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2016.11.041_bib0050","first-page":"565","article-title":"Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia","volume":"43","author":"Galanello","year":"2003","journal-title":"J. Clin. Pharmacol."},{"issue":"9369","key":"10.1016\/j.biopha.2016.11.041_bib0055","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(03)13309-0","article-title":"Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial","volume":"361","author":"Nisbet-Brown","year":"2003","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.biopha.2016.11.041_bib0060","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ijantimicag.2015.11.012","article-title":"Efavirenz pharmacogenetics in a cohort of Italian patients","volume":"47","author":"Cusato","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"3","key":"10.1016\/j.biopha.2016.11.041_bib0065","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/tpj.2014.65","article-title":"Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness","volume":"15","author":"Cusato","year":"2014","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.biopha.2016.11.041_bib0070","article-title":"Deferasirox pharmacokinetic evaluation in beta-thalassaemia paediatric patients","author":"Allegra","year":"2016","journal-title":"J. Pharm. Pharmacol."},{"issue":"9","key":"10.1016\/j.biopha.2016.11.041_bib0075","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00228-016-2070-9","article-title":"Deferasirox AUC efficacy cutoff and role of pharmacogenetics","volume":"72","author":"Allegra","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2016.11.041_bib0080","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jchromb.2012.02.047","article-title":"A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients","volume":"893\u2013894","author":"De Francia","year":"2012","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"issue":"19","key":"10.1016\/j.biopha.2016.11.041_bib0085","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1182\/blood-2009-05-222729","article-title":"Deferasirox pharmacokinetics in patients with adequate versus inadequate response","volume":"114","author":"Chirnomas","year":"2009","journal-title":"Blood"},{"issue":"Suppl. (4)","key":"10.1016\/j.biopha.2016.11.041_bib0090","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1136\/gut.2006.091108","article-title":"Guidelines for management of patients with a short bowel","volume":"55","author":"Nightingale","year":"2006","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.biopha.2016.11.041_bib0095","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2217\/pgs-2015-0001","article-title":"Role of pharmacogenetics on deferasirox AUC and efficacy","volume":"17","author":"Cusato","year":"2016","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.biopha.2016.11.041_bib0100","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ajh.2830420116","article-title":"Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major","volume":"42","author":"Brittenham","year":"1993","journal-title":"Am. J. Hematol."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332216317887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332216317887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:47:30Z","timestamp":1773874050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332216317887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":20,"alternative-id":["S0753332216317887"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2016.11.041","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous \u03b2-thalassaemia","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2016.11.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}